Evolus (EOLS) Debt Ratio (2017 - 2026)

Evolus' (EOLS) quarterly Debt Ratio came in at 0.71 in Q1 2026, up 24.17% YoY from 0.57 in Q1 2025, and up 9.6% on a QoQ basis from 0.65 in Q4 2025.

Evolus (EOLS) Debt Ratio (2017 - 2026) Analysis & Trends

Evolus (EOLS) has 10 years of Debt Ratio data on file, last reported at 0.71 in Q1 2026.

Quarterly Debt Ratio rose 24.17% year-over-year to 0.71 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.71 (up 24.17% YoY) and the FY2025 annual result came in at 0.65, up 23.8% from the prior year.
Debt Ratio grew to 0.71 in Q1 2026, from 0.65 in the prior quarter.
In the past five years, Debt Ratio ranged from a high of 0.71 in Q1 2026 to a low of 0.32 in Q1 2022.
A 5-year average of 0.53 and a median of 0.53 in 2024 frame the typical range for Debt Ratio.
Annual changes were most pronounced in 2023 — Debt Ratio jumped 65.44% — and 2024, when it decreased 17.96%.
Tracing EOLS's Debt Ratio over 5 years: stood at 0.4 in 2022, then soared by 57.69% to 0.64 in 2023, then slipped by 17.96% to 0.52 in 2024, then gained by 23.8% to 0.65 in 2025, then gained by 9.6% to 0.71 in 2026.
The last three Debt Ratio figures came in at 0.71 (Q1 2026), 0.65 (Q4 2025), and 0.67 (Q3 2025), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Debt Ratio (Qtr)
1	Haleon	44.51 Bn	43.55 Bn	-	-0.13
2	Teva Pharmaceutical Industries	43.52 Bn	39.86 Bn	2.15 Bn	0.42
3	Zoetis	32.43 Bn	30.75 Bn	1.05 Bn	0.60
4	Takeda Pharmaceutical	28.63 Bn	22.83 Bn	5.10 Bn	0.32
5	United Therapeutics	21.87 Bn	19.21 Bn	683.80 Mn	-
6	Viatris	18.98 Bn	18.09 Bn	1.46 Bn	0.38
7	Neurocrine Biosciences	15.43 Bn	15.04 Bn	935.80 Mn	-
8	Elanco Animal Health	12.02 Bn	11.49 Bn	798.00 Mn	0.29
9	Dr Reddys Laboratories	10.14 Bn	9.98 Bn	-	0.12
10	Evolus	552.49 Mn	507.32 Mn	57.18 Mn	0.63

Download Data